Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

2.660 +0.060 (+2.31%)
Streaming Delayed Price Updated: 10:32 AM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,721
Open 2.650
Bid (Size) 2.610 (100)
Ask (Size) 2.660 (3,600)
Prev. Close 2.600
Today's Range 2.650 - 2.750
52wk Range 2.430 - 20.59
Shares Outstanding 3,192,040
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose 
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-23.3%
-23.3%
1 Month
+4.7%
+4.7%
3 Month
-17.9%
-17.9%
6 Month
-18.4%
-18.4%
1 Year
-64.8%
-64.8%

More News

Read More
News headline image
Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Expands Global Intellectual Property Estate
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Cellectar Biosciences ↗
Via Benzinga
News headline image
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗
Via Stocktwits
Topics Supply Chain
News headline image
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
What is the current price of Cellectar Biosciences, Inc. - Common Stock?
The current price of Cellectar Biosciences, Inc. - Common Stock is 2.660
When was Cellectar Biosciences, Inc. - Common Stock last traded?
The last trade of Cellectar Biosciences, Inc. - Common Stock was at 05/01/26 10:32 AM ET
What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 8.49M
How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
Cellectar Biosciences, Inc. - Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.